Search
Mar 4
Nuvalent's CEO on overcoming kinase resistance and selectivity for its precision oncology medicines
Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1.
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.
bottom of page